Filter Results:
(449)
Show Results For
- All HBS Web
(637)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
Show Results For
- All HBS Web
(637)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
Sort by
- 12 Mar 2013
- First Look
First Look: March 12
A. Arnaout Publication:Nature Biotechnology Abstract Advances in biotechnology have fueled the generation of unprecedented quantities of data across the life sciences. However, finding analysts who can... View Details
Keywords: Sean Silverthorne
- 20 Nov 2006
- Research & Ideas
Open Source Science: A New Model for Innovation
coming up with a solution that could be off-the-shelf. So when they actually see solutions from this type of method, they're blown away. Recently, an internal science team at a U.S.-based major biotechnology firm was assigned to develop a... View Details
Keywords: by Martha Lagace
- 22 Sep 2020
- Research & Ideas
Recessions Push Some Entrepreneurs to Launch Too Soon
an associate professor at University of Lausanne, studied 3,025 US founders from 2005 to 2012 and their 1,747 startups in the biotechnology and medical device sectors during previous economic downturns. Their research was conducted before... View Details
Keywords: by Sean Silverthorne
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
challenges, not on the hard work of winning hearts and minds, Shapiro ultimately lost his company. He was forced to sell Monsanto to Pharmacia-Upjohn, which bought it for its pharmaceutical division, valuing the agricultural biotechnology... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- 22 Nov 2016
- First Look
November 22, 2016
commercial implications—the technology would be immensely important to biotechnology firms looking to develop gene therapy products and was, therefore, sure to generate strong revenues for whichever entity owned the IP—but would also... View Details
Keywords: Sean Silverthorne
- 2020
- Book
Work, Mate, Marry, Love: How Machines Shape Our Human Destiny
By: Debora L. Spar
Covering a time frame that ranges from 8000 BC to the present, and drawing upon both Marxist and feminist theories, the book argues that nearly all the decisions we make in our most intimate lives—whom to marry, how to have children, how to have sex, how to think about... View Details
Keywords: Innovation; Family; Women; Reproduction; Artificial Intelligence; Robots; Gender; Demography; History; Innovation and Invention; Relationships; Society; Information Technology; AI and Machine Learning; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Africa; Asia; Europe; Latin America; North and Central America
Spar, Debora L. Work, Mate, Marry, Love: How Machines Shape Our Human Destiny. New York: Farrar, Straus and Giroux, 2020.
- May 2025
- Supplement
Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (D)
By: Linda A. Hill and Lydia Begag
This fourth installment in the Pfizer Global Clinical Supply (GCS) transformation case series highlights how over a decade of cultural and digital evolution positioned GCS to meet unprecedented global challenges. In 2011, Michael Ku became the Vice President of GCS and... View Details
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
Keywords: Clusters; Economics; Industry Clusters; Economy; Growth and Development; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; San Diego
Porter, Michael E. "Clusters of Innovation Initiative: San Diego." Council on Competitiveness, Washington, DC, May 2001. (Report.)
- October 2012
- Supplement
Aqua Bounty Courseware
By: Lucy White and Steve Burn-Murdoch
Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and... View Details
- December 2003 (Revised April 2004)
- Case
Dragon's Teeth Vineyards
By: Alan D. MacCormack, Marius Leibold, Sven Voelpel and Kerry Herman
Dragon's Teeth Vineyards (DTV) is a South African wine producer that is considering whether to use genetically modified organisms (GMOs) in its wine-making process. GMOs promise to lower the costs of wine production significantly through increased yields and reduced... View Details
Keywords: Technological Innovation; Growth and Development Strategy; Genetics; Transition; Brands and Branding; Product Development; Product Design; Organizational Change and Adaptation; Technology Adoption; Biotechnology Industry; Biotechnology Industry; South Africa
MacCormack, Alan D., Marius Leibold, Sven Voelpel, and Kerry Herman. "Dragon's Teeth Vineyards." Harvard Business School Case 604-069, December 2003. (Revised April 2004.)
- February 1999
- Teaching Note
Pioneer Hi-Bred International, Inc.: Supply Management TN
By: Francis Aguilar, Paul Clark and Xin Xi He
Teaching Note for (9-898-238) and (9-898-239). View Details
- 26 Jul 2016
- Working Paper Summaries
The Impact of the Entry of Biosimilars: Evidence from Europe
- 21 Apr 2014
- Research & Ideas
Bio-Piracy: When Western Firms Usurp Eastern Medicine
In May 1995, two scientists at the University of Mississippi were granted an American patent for the use of turmeric to treat flesh wounds. Soon thereafter, an Indian research organization won a lawsuit challenging the novelty of the patent. As it turned out, Indians... View Details
- April 1995 (Revised April 1999)
- Teaching Note
Aberlyn Capital Management TN
By: Josh Lerner
Teaching Note for (9-294-083). View Details
- March 2025 (Revised April 2025)
- Teaching Note
Moving Science: The Rowland Institute at Harvard
By: Maria Roche
Teaching Note for HBS Case No. 724-441. View Details
- 20 Mar 2012
- First Look
First Look: March 20
Market Governments—Qualitative Evidence from a Biotechnology Multinational Authors:Prithwiraj Choudhury, James Geraghty, and Tarun Khanna Publication:Global Strategy Journal 2, no. 1 (February 2012) Abstract We build on the emerging... View Details
Keywords: Sean Silverthorne
- 03 Nov 2015
- First Look
November 3, 2015
quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to... View Details
Keywords: Sean Silverthorne
- 11 Nov 2015
- Working Paper Summaries
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
- 24 Sep 2007
- Research & Ideas
The FDA: What Will the Next 100 Years Bring?
The U.S. Food and Drug Administration, which was created by the passage of the 1906 Federal Food and Drugs Act, regulates companies and industries accounting for one-quarter of all consumer spending, roughly $1.5 trillion worth of consumer goods and medicines. It... View Details
- July 1993
- Case
Genzyme Corporation: A Financing History
By: Timothy A. Luehrman and Andrew D. Regan
Genzyme Corp.'s financing history is unusual compared to most biotech companies. This case presents the sequence of financings employed by Genzyme, along with the product--market and corporate-development strategies adopted by Henri Termeer, Genzyme's CEO. As such, the... View Details
Keywords: History; Marketing Strategy; Financing and Loans; Business Strategy; Growth and Development Strategy; Biotechnology Industry
Luehrman, Timothy A., and Andrew D. Regan. "Genzyme Corporation: A Financing History." Harvard Business School Case 294-005, July 1993.